Search clinical trials for: acquired T790M mutation

Total 7158 results

National Cancer Institute (NCI)

Completed

Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib

Lung Neoplasms | Lung Adenocarcinoma

United States
Novartis Pharmaceuticals

Completed

A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies

Advanced Non-small Cell Lung Cancer

Spain, Canada, Germany, Korea, Republic of, Taiwan, United States, Japan, Netherlands, Singapore
Tianjin Medical University Cancer Institute and...

Recruiting

Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial

Non-small Cell Lung Cancer | EGFR Activating Mutation | EGFR-TKI Resistant Mutation | Cell Cycle Deregulation

China
Pusan National University Hospital

Recruiting

Feasibility of Intratumoral Washing Fluid for Detecting EGFR Mutations in Lung Cancer

Non Small Cell Lung Cancer | EGFR Gene Mutation

Korea, Republic of
Shanghai EpimAb Biotherapeutics Co., Ltd.
Labcorp Corporation of America Holdings, Inc

Not yet recruiting

EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Advanced Lung Non-Small Cell Carcinoma | EGFR Mutation-Related Tumors

United States, China
Gamaleya Research Institute of Epidemiology and...
MSD Pharmaceuticals LLC

Not yet recruiting

HIV A6 Genome In ART Unsuccessful Patients On DOR (HIV-A6-DOR)

Virus-HIV
N.N. Blokhin National Medical Research Center of...

Recruiting

Osimertinib for Russian EGFR T790M Mutation-positive NSCLC Patients Who Progressed on or After EGFR TKI Therapy (TRUST)

Non Small Cell Lung Cancer | EGFR Gene Mutation | T790M

Russian Federation
Black Diamond Therapeutics, Inc.

Recruiting

Phase 1/2 Study of BDTX-1535 in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations

Non-Small Cell Lung Cancer | NSCLC | Metastatic Lung Cancer | Metastatic Lung Non-Small Cell Carcinoma | EGF-R Positive Non-Small Cell Lung Cancer | Advanced Lung Carcinoma | EGFR-TKI Resistant Mutation | Advanced Non-Small Cell Squamous Lung Cancer | Epidermal Growth Factor Receptor C797S | Epidermal...

United States
Sanford Health
National Ataxia Foundation; Beyond Batten Disease Foundation; Pitt Hopkins Research... and other collaborators

Recruiting

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford (CoRDS)

Mitochondrial Diseases | Retinitis Pigmentosa | Myasthenia Gravis | Eosinophilic Gastroenteritis | Multiple System Atrophy | Leiomyosarcoma | Leukodystrophy | Anal Fistula | Spinocerebellar Ataxia Type 3 | Friedreich Ataxia | Kennedy Disease | Lyme Disease | Hemophagocytic Lymphohistiocytosis | Spinocerebellar Ataxia... and other conditions

United States, Australia
Novartis Pharmaceuticals

Terminated

Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy (GEOMETRY-E)

Carcinoma, Non-Small-Cell Lung

Japan, Korea, Republic of, Singapore
University of Cologne

Completed

EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer Harboring Activating EGFR Mutations (EATON)

Bronchial Neoplasms

Spain, Germany
Novartis Pharmaceuticals

Active, not recruiting

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

EGFR-mutant Non-small Cell Lung Cancer

Taiwan, Germany, Canada, Italy, Singapore, Hong Kong
AstraZeneca

Completed

AZD9291 First Time In Patients Ascending Dose Study (AURA)

Advanced Non Small Cell Lung Cancer | Advanced (Inoperable) Non Small Cell Lung Cancer

United States, France, Germany, Korea, Republic of, Taiwan, United Kingdom, Spain, Italy, Japan, Australia
Blueprint Medicines Corporation

Active, not recruiting

(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC

Neoplasms | Neoplasms by Histologic Type | Lung Diseases | Neoplasms by Site | Adenocarcinoma | Carcinoma | Carcinoma, Non-Small-Cell Lung | Lung Neoplasms | Respiratory Tract Neoplasms | Thoracic Neoplasms | Carcinoma, Bronchogenic | Bronchial Neoplasms | Neoplasms, Nerve Tissue | EGF-R Positive Non-Small Cell Lung... and other conditions

United States, Canada, Taiwan, Korea, Republic of, Singapore, Japan, United Kingdom, France, Netherlands, Spain
AstraZeneca

Completed

Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive Tumours (AURA2)

Non Small Cell Lung Cancer

Italy, United States, Canada, Korea, Republic of, Japan, Taiwan, Hong Kong, Spain
Thoraxklinik-Heidelberg gGmbH
AstraZeneca

Completed

Real-world Analysis of Workup at Disease Progression and Implementation of Osimertinib for EGFR+ NSCLC

EGFR Positive Non-small Cell Lung Cancer

Germany
AstraZeneca

Active, not recruiting

AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (AURA3)

Anticancer Treatment

United States, France, Germany, Spain, Sweden, United Kingdom, Canada, Italy, Korea, Republic of, Hungary, Japan, Russian Federation, China, Taiwan, Hong Kong, Netherlands, Australia, Mexico
Shanghai Junshi Bioscience Co., Ltd.

Completed

A Study of Toripalimab+ Pemetrexed Plus Carboplatin in Patients With EGFR-mutation Positive and T790M Negative After Progression on EGFR-TKI Treatment (JS001)

NSCLC

China
Yuhan Corporation

Completed

Retrospective, External Comparator Study of Lazertinib as the 2nd-Line Treatment in Patients With EGFR Mutation+ NSCLC

Non-small Cell Lung Cancer
AstraZeneca

Completed

Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours (CAURAL)

Locally Advanced or Metastatic EGFR T790M+ NSCLC

Canada, Korea, Republic of, Taiwan
South East Asia Research Collaboration with Hawaii
The Thai Red Cross AIDS Research Centre; Cooper Human Systems

Completed

Efficacy of VHM After Treatment Interruption in Subjects Initiating ART During Acute HIV Infection

Acute HIV Infection

Thailand
Michael Hopp
Boehringer Ingelheim

Active, not recruiting

AFAMOSI: Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients With EGFRmutated/T790M Mutation Negative Nonsquamous NSCLC

Non-squamous NSCLC

Germany
G1 Therapeutics, Inc.

Completed

G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung | Lung Cancer | Non-small Cell Lung Cancer

United States
Elizabeth Glaser Pediatric AIDS Foundation
Janssen, LP

Active, not recruiting

Characteristics and Outcomes of Patients Who Received Etravirine and/or Darunavir (NewHorizon)

HIV/AIDS

Cameroon, Kenya, Lesotho, Swaziland, Uganda
First Affiliated Hospital of Zhejiang University

Terminated

Osimertinib Combined With Anlotinib in EGFR T790M Mutated NSCLC Patients With Progression on Osimertinib Treatment

Non Small Cell Lung Cancer

China
Sihuan Pharmaceutical Holdings Group Ltd.

Terminated

XZP-5809-TT1 Tablets in Patients With T790M Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer

Non Small Cell Lung Cancer

China
AstraZeneca

Active, not recruiting

Phase II Single Arm Study of AZD9291 to Treat NSCLC Patients in Asia Pacific (AURA17)

Non-Small Cell Lung Cancer

Korea, Republic of, China, Australia
Checkpoint Therapeutics, Inc.

Completed

Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors

Lung Diseases | Adenocarcinoma | Carcinoma, Non-Small-Cell Lung | Lung Neoplasms

United States, Thailand, New Zealand, Australia, Poland
Sunshine Lake Pharma Co., Ltd.

Active, not recruiting

Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative

Non-small Cell Lung Cancer

China
Fundación GECP

Completed

Osimertinib in Subjects With Advanced Non-Small Cell Lung Cancer EGFR-T790M Mutation-positive (OSIREX)

Non Small Cell Lung Cancer

Spain
Beta Pharma Shanghai

Completed

A Phase IIb Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients With T790M Mutation Positive

NSCLC

China
Beta Pharma Shanghai

Completed

BPI-7711 Capsule in Patients With EGFR Mutation T790M Positive Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
AstraZeneca
Parexel

Completed

Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC (ASTRIS)

Lung Cancer

Canada, Denmark, Italy, Spain, Belgium, Korea, Republic of, Brazil, China, Taiwan, Australia, Austria, United Kingdom, Sweden, Argentina, Saudi Arabia, Ireland
Exosome Diagnostics, Inc.

Active, not recruiting

Detection of Either the EML4-ALK Gene Rearrangements or the T790M EGFR Mutation in the Plasma of Advanced NSCLC Patients

Carcinoma, Non-Small-Cell Lung

United States
Samsung Medical Center

Active, not recruiting

Study of AZD9291 in NSCLC Patients Harboring T790M Mutation Who Failed EGFR TKI and With Brain and/or LMS

Non-Small Cell Lung Cancer With EGFR T790M Mutation | With Brain and/or Leptomeningeal Metastasis | Failed Tyrosine Kinase Inhibitors

Korea, Republic of
Yuhan Corporation

Active, not recruiting

Clinical Trial of YH25448 in Patients With EGFR Mutation Positive Advanced NSCLC

EGFR Gene Mutation

Korea, Republic of
Pfizer

Terminated

Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)

Non-Small Cell Lung Cancer

United States, Korea, Republic of, Australia, Japan
AstraZeneca
iOMEDICO AG, Freiburg, Germany

Completed

PANORAMA - Real World Molecular Testing, Treatment Patterns, and Clinical Outcomes EGFR Mutation-Positive NSCLC (PANORAMA)

Carcinoma, Non-Small-Cell Lung

Germany
Hanmi Pharmaceutical Company Limited

Terminated

Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung

Non Small Cell Lung Cancer

United States, Australia, Italy, Korea, Republic of, Spain, Germany, Malaysia, Taiwan, Canada, Philippines
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb; Boehringer Ingelheim

Completed

Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)

Lung Cancer | Non-small Cell Lung Cancer (NSCLC)

United States
Fudan University

Unknown

Almonertinib/Pemetrexed/Carboplatin in EGFR T790M+ Advanced Lung Cancer (APPEAL)

Lung Cancer, Non-small Cell | EGFR Gene Mutation | EGFR T790M

China
Guangzhou Institute of Respiratory Disease
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Efficacy and Safety of Toripalimab (JS001) Combined With Pemetrexed and Anlotinib for Patients With T790M Positive Non-Small Cell Lung Cancer After Osimertinib Resistance

IIIb/IV NSCLC With T790M Positive Mutations Failed to Osimertinib Therapy

China
The First Hospital of Jilin University

Unknown

Apatinib Combined With Chemotherapy for NSCLC Patients Without T790M Mutation

Non Small Cell Lung Cancer

China
Spanish Lung Cancer Group

Completed

T790M Mutation Testing in Blood by Different Methodologies

NSCLC Stage IV

Spain
Haihe Biopharma Co., Ltd.

Unknown

Glumetinib Combined With Osimertinib in the Treatment of Relapsed and Metastatic Non-small Cell Lung Cancer Patients Who Failed to Receive EGFR Inhibitors

Negative T790M Mutation and Met Amplification

China
Hoosier Cancer Research Network
Clovis Oncology, Inc.

Completed

PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations

Breast Cancer

United States
Astellas Pharma Global Development, Inc.

Completed

A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations

Non-Small-Cell Lung Cancer (NSCLC) | Epidermal Growth Factor Receptor Mutations

United States
AstraZeneca
Medpace, Inc.

Completed

Resistance & Activating Mutations Diagnosed Among NSCLC Community Dwelling EGFR Mutation Positive Patients (RADIANCE)

Non-small Cell Lung Cancer

United States, Canada
Astellas Pharma Inc

Terminated

An Open Study of ASP8273 in Patients With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations

Non-small Cell Lung Cancer

Japan, Korea, Republic of, Taiwan
Konkuk University Medical Center
Hanmi Pharmaceutical Company Limited

Completed

Olmutinib Trial in T790M (+) NSCLC Patients Detected by Liquid Biopsy Using BALF Extracellular Vesicular DNA

Non Small Cell Lung Cancer

Korea, Republic of

Search clinical trials for: acquired T790M mutation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malawi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations